- Home
- CRT vs BYSI Comparison
CRT vs BYSI Comparison
Compare CRT & BYSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRT
- BYSI
- Stock Information
- Founded
- CRT 1991
- BYSI 2010
- Country
- CRT United States
- BYSI United States
- Employees
- CRT N/A
- BYSI N/A
- Industry
- CRT Oil & Gas Production
- BYSI Biotechnology: Pharmaceutical Preparations
- Sector
- CRT Energy
- BYSI Health Care
- Exchange
- CRT Nasdaq
- BYSI Nasdaq
- Market Cap
- CRT 60.9M
- BYSI 72.1M
- IPO Year
- CRT 1992
- BYSI 2017
- Fundamental
- Price
- CRT $10.66
- BYSI $1.79
- Analyst Decision
- CRT
- BYSI
- Analyst Count
- CRT 0
- BYSI 0
- Target Price
- CRT N/A
- BYSI N/A
- AVG Volume (30 Days)
- CRT 27.5K
- BYSI 10.8K
- Earning Date
- CRT 01-01-0001
- BYSI 01-01-0001
- Dividend Yield
- CRT 8.04%
- BYSI N/A
- EPS Growth
- CRT N/A
- BYSI N/A
- EPS
- CRT 1.13
- BYSI N/A
- Revenue
- CRT $7,711,133.00
- BYSI $1,876,000.00
- Revenue This Year
- CRT N/A
- BYSI N/A
- Revenue Next Year
- CRT N/A
- BYSI N/A
- P/E Ratio
- CRT $9.44
- BYSI N/A
- Revenue Growth
- CRT N/A
- BYSI 21.03
- 52 Week Low
- CRT $8.88
- BYSI $1.07
- 52 Week High
- CRT $17.72
- BYSI $4.00
- Technical
- Relative Strength Index (RSI)
- CRT 50.85
- BYSI 56.87
- Support Level
- CRT $10.23
- BYSI $1.61
- Resistance Level
- CRT $11.36
- BYSI $1.88
- Average True Range (ATR)
- CRT 0.34
- BYSI 0.10
- MACD
- CRT 0.01
- BYSI 0.00
- Stochastic Oscillator
- CRT 38.05
- BYSI 66.67
About CRT Cross Timbers Royalty Trust
Cross Timbers Royalty Trust is a United States based trust. Its principal asset is the net profits interests. The net profits interests are derived from producing royalty, overriding royalty interests, and working interests properties. The underlying properties of the trust include producing properties in Texas, Oklahoma, and New Mexico.
About BYSI BeyondSpring Inc.
BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It has two reportable segments Plinabulin pipeline and the TPD platform.